Technological advances combined with an improved understanding of the genetic basis of cancer has revolutionised the way we manage cancer. Utilising the patient’s particular genomic profile, clinicians can now assess the risk of hereditary cancer for the patient and the patient’s family, also tailor the best treatment options.

BGI’s SENTIS™ Cancer+Discovery provides clinicians with one of the market’s most comprehensive and accurate Next Generation Sequencing (NGS) based testing solution for the identification of clinically actionable mutations and the discovery of novel variants with important functions in cancer. Supporting both tissue sample and liquid biopsy, the panel offers whole exon coverage of 688 cancer-related genes and interrogates the most common types of alterations, including SNVs, Indels, CNVs and fusions in solid tumours.